QSAM Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QSAM research report →
Companyqsambio.com
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical.
- CEO
- Douglas R. Baum
- IPO
- 2012
- Employees
- 4
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $18.44K
- P/E
- -6.67
- P/S
- 0.00
- P/B
- 43.58
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1617.91%
- ROIC
- -579.91%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,393,126 · 27.68%
- EPS
- $-1.24 · 64.06%
- Op Income
- $-3,942,510
- FCF YoY
- -5.02%
Performance & Tape
- 52W High
- $16600.00
- 52W Low
- $4.10
- 50D MA
- $649.00
- 200D MA
- $166.26
- Beta
- 1.81
- Avg Volume
- 6.09K
Get TickerSpark's AI analysis on QSAM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 2, 24 | Piazza C Richard | sell | 188 |
| May 2, 24 | Baum Douglas R | sell | 188 |
| May 2, 24 | Link Jr. Charles J | sell | 41 |
| May 2, 24 | Nelson Christopher M. | sell | 91 |
| May 2, 24 | Sax Adriann | sell | 5 |
| May 2, 24 | King Adam | sell | 11 |
| Jan 15, 23 | Checkmate Strategic Capital 2, LLC | other | 50,000 |
| Dec 19, 23 | Checkmate Strategic Capital 2, LLC | other | 50,000 |
| Feb 6, 24 | Checkmate Strategic Capital 2, LLC | other | 156 |
| Feb 6, 24 | Baum Douglas R | other | 1,302 |
Our QSAM Coverage
We haven't published any research on QSAM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate QSAM Report →